Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 59Colorectal Neoplasms 45Rectal Neoplasms 35Stomach Neoplasms 27Pancreatic Neoplasms 27Neoplasm Metastasis 24Neoplasms 19Colonic Neoplasms 18Triple Negative Breast Neoplasms 7Esophageal Neoplasms 6Adenocarcinoma 6Liver Neoplasms 5Brain Neoplasms 5Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Ovarian Neoplasms 3Head and Neck Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Ovarian Epithelial 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms, Unknown Primary 2Melanoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Carcinoma 2Breast Neoplasms, Male 2

Interventions

vandetanib 2rovalpituzumab tesirine 1pentetreotide 1lenvatinib 1cabozantinib 1Sorafenib 1Octreotide 1Lithium Carbonate 1Irinotecan 1Imatinib Mesylate 1Dexamethasone 1Dacarbazine 1Capecitabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Medullary × Capecitabine × Clear all
NCT00354523 2014-12-17

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
21 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡